JPMorgan Chase & Co. Issues Pessimistic Forecast for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its price objective dropped by JPMorgan Chase & Co. from $9.00 to $7.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the health services provider’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 30.23% from the stock’s current price.

Several other equities research analysts have also recently issued reports on TDOC. Bank of America raised shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Thursday, February 26th. TD Cowen reduced their target price on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Thursday, February 26th. Citigroup decreased their price target on shares of Teladoc Health from $9.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Stifel Nicolaus lowered their price target on Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a report on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Teladoc Health in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.72.

Teladoc Health Stock Performance

TDOC stock opened at $5.38 on Friday. Teladoc Health has a twelve month low of $4.40 and a twelve month high of $9.77. The firm has a market cap of $958.88 million, a price-to-earnings ratio of -4.71 and a beta of 2.13. The business’s fifty day simple moving average is $5.62 and its two-hundred day simple moving average is $7.05. The company has a quick ratio of 2.67, a current ratio of 2.77 and a debt-to-equity ratio of 0.72.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. The business’s revenue was up .3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.28) earnings per share. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Analysts predict that Teladoc Health will post -1.16 earnings per share for the current year.

Insider Transactions at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 27,731 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $5.49, for a total transaction of $152,243.19. Following the transaction, the chief executive officer owned 364,784 shares of the company’s stock, valued at approximately $2,002,664.16. This trade represents a 7.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.58% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teladoc Health

Several hedge funds have recently modified their holdings of TDOC. Corient Private Wealth LLC boosted its stake in shares of Teladoc Health by 236.6% during the fourth quarter. Corient Private Wealth LLC now owns 37,692 shares of the health services provider’s stock valued at $264,000 after purchasing an additional 26,494 shares in the last quarter. Alpine Global Management LLC bought a new position in Teladoc Health in the fourth quarter worth approximately $187,000. Virtu Financial LLC purchased a new stake in Teladoc Health during the fourth quarter worth $854,000. Mackenzie Financial Corp lifted its holdings in Teladoc Health by 38.6% during the fourth quarter. Mackenzie Financial Corp now owns 165,550 shares of the health services provider’s stock worth $1,157,000 after buying an additional 46,090 shares during the period. Finally, Empowered Funds LLC boosted its position in Teladoc Health by 1.9% during the 4th quarter. Empowered Funds LLC now owns 742,305 shares of the health services provider’s stock valued at $5,196,000 after acquiring an additional 14,029 shares in the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates (improvements to Q1–Q4 2026, FY2026 and FY2027), which narrows expected losses and helps valuation/earnings outlook. Zacks Research coverage
• Positive Sentiment: Deutsche Bank upgraded TDOC to Buy, citing BetterHelp momentum, AI initiatives and international expansion — contributing to renewed analyst interest that can lift demand. Deutsche Bank upgrade
• Positive Sentiment: Coverage pieces highlight an earnings beat and strategic plans (BetterHelp, AI, international) that have put TDOC back on investors’ radar and supported recent short‑term gains. Valuation analysis
• Neutral Sentiment: Market notes point to volatility and short‑term moves relative to the broader market — useful context for traders but not a direct company catalyst. Market note
• Negative Sentiment: JPMorgan lowered its price target from $9 to $7 and assigned a “neutral” rating — a reduction in expected upside that can weigh on sentiment even though the new target still implies upside from current levels. JPMorgan note
• Negative Sentiment: Insider selling: CEO Charles Divita III sold 27,731 shares at ~$5.49 (disclosed in an SEC filing), reducing his stake by ~7% — a sell by the CEO that some investors may view negatively. SEC filing

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.